Pharvaris N.V. (PHVS)
PHVSNASDAQ-GSBiotechnology: Pharmaceutical Preparations
$33.92
-0.2600 (-0.76%) today
Regular session, Nov 12, 11:18 AM ET
- Market cap
- $2.36bn
- P/E
- –
- EPS, last 4 quarters
- $-3.05
- Dividend yield
- –
- Day range
- $33.00 to $34.54
- 52-week range
- $22.78 to $43.25
- Average volume
- –
- Previous close
- $34.18
Analysts
12 coveringBuy12 buy, 0 hold, 0 sell
Targets a year out average $61.33, +80.8% from here
Earnings
next estimate $-0.8200Next report
Sep 2025
+10.3%
Dec 2025
–
Mar 2026
+7.9%
Jun 2026
-9.5%
estimate reported, and the surprise
Financials
| Quarter | Dec 2020 |
|---|---|
| Revenue | – |
| Gross profit | – |
| Operating income | -$12.72m |
| Net income | -$13.71m |
News
8 latest- Weekly Buzz: RHHBY, NVS, PFE Win FDA Nod; CRBU Scales Back; PCVX, ABBV Report Positive Trial Data RTTNews · Oct 9, 2026
- Pharvaris' Deucrictibant XR Cuts HAE Attack Rate By 83%; Plans NDA Filing In H1 2027 RTTNews · Oct 9, 2026
- Pharvaris Study Shows HAE Patients Prefer Oral Prophylaxis Over Injections RTTNews · Oct 5, 2026
- iShares Core MSCI Europe ETF Experiences Big InflowBNK Invest · Sep 29, 2026
- PHVS Stock Rises 10% in a Month: What Is Driving the Rally?Zacks · Sep 15, 2026
- Pharvaris N.V. Consensus Price Target Raised 20.08% to $59.77Fintel · Sep 14, 2026
- Weekly Buzz: JNJ Wins FDA Nod; AXGN, HCWB Strike Deals; ROIV, AZN, GPCR Lead Clinical Trials RTTNews · Sep 11, 2026
- Wedbush Reaffirms Outperform Rating On Pharvaris; PT $42 After Positive Phase 3 CHAPTER-3 Data RTTNews · Sep 9, 2026
The company
Pharvaris is a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs in bradykinin-mediated conditions, including all types of bradykinin-mediated angioedema. Pharvaris' aspiration is to offer therapies with injectable-like efficacy, a well-tolerated profile, and the convenience of oral administration to prevent and treat bradykinin-mediated angioedema attacks. By delivering on this aspiration, Pharvaris aims to provide a new standard of care in bradykinin-mediated angioedema.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-GS
- Region
- Europe
- Website
- pharvaris.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.